A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

October 14, 2022

Study Completion Date

August 1, 2025

Conditions

Malignant DiseaseSolid TumorAcute Myeloid LeukemiaMyelodysplastic SyndromesCancerRelapsed Hematologic Malignancy

Interventions

DRUG

Atorvastatin

Atorvastatin tablet, 80mg

Trial Locations (1)

University of Kansas Cancer Center - CRC, Fairway

All Listed Sponsors

lead

Joaquina Baranda

OTHER